Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia
The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/11/2459 |
| _version_ | 1797597023687409664 |
|---|---|
| author | Yushu Qin Donalyn Bily Makayla Aguirre Ke Zhang Linglin Xie |
| author_facet | Yushu Qin Donalyn Bily Makayla Aguirre Ke Zhang Linglin Xie |
| author_sort | Yushu Qin |
| collection | DOAJ |
| description | The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood, although it is known that the pathologic placenta plays a crucial role. Studies have shown that PPARγ, a transcription factor involved in glucose and lipid metabolism, may have a critical role in the etiology of these complications. While PPARγ agonists are FDA-approved drugs for Type 2 Diabetes Mellitus, their safety during pregnancy is not yet established. Nevertheless, there is growing evidence for the therapeutic potential of PPARγ in the treatment of PE using mouse models and in cell cultures. This review aims to summarize the current understanding of the mechanism of PPARγ in placental pathophysiology and to explore the possibility of using PPARγ ligands as a treatment option for pregnancy complications. Overall, this topic is of great significance for improving maternal and fetal health outcomes and warrants further investigation. |
| first_indexed | 2024-03-11T03:00:57Z |
| format | Article |
| id | doaj.art-acda9336752f466c9a494480fb67a9b8 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T03:00:57Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-acda9336752f466c9a494480fb67a9b82023-11-18T08:20:23ZengMDPI AGNutrients2072-66432023-05-011511245910.3390/nu15112459Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and PreeclampsiaYushu Qin0Donalyn Bily1Makayla Aguirre2Ke Zhang3Linglin Xie4Department of Nutrition, Texas A&M University, College Station, TX 77843, USADepartment of Nutrition, Texas A&M University, College Station, TX 77843, USADepartment of Nutrition, Texas A&M University, College Station, TX 77843, USADepartment of Nutrition, Texas A&M University, College Station, TX 77843, USADepartment of Nutrition, Texas A&M University, College Station, TX 77843, USAThe increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood, although it is known that the pathologic placenta plays a crucial role. Studies have shown that PPARγ, a transcription factor involved in glucose and lipid metabolism, may have a critical role in the etiology of these complications. While PPARγ agonists are FDA-approved drugs for Type 2 Diabetes Mellitus, their safety during pregnancy is not yet established. Nevertheless, there is growing evidence for the therapeutic potential of PPARγ in the treatment of PE using mouse models and in cell cultures. This review aims to summarize the current understanding of the mechanism of PPARγ in placental pathophysiology and to explore the possibility of using PPARγ ligands as a treatment option for pregnancy complications. Overall, this topic is of great significance for improving maternal and fetal health outcomes and warrants further investigation.https://www.mdpi.com/2072-6643/15/11/2459PPARγrosiglitazonetrophoblastplacentagestational diabetes mellituspreeclampsia |
| spellingShingle | Yushu Qin Donalyn Bily Makayla Aguirre Ke Zhang Linglin Xie Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia Nutrients PPARγ rosiglitazone trophoblast placenta gestational diabetes mellitus preeclampsia |
| title | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
| title_full | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
| title_fullStr | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
| title_full_unstemmed | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
| title_short | Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia |
| title_sort | understanding pparγ and its agonists on trophoblast differentiation and invasion potential therapeutic targets for gestational diabetes mellitus and preeclampsia |
| topic | PPARγ rosiglitazone trophoblast placenta gestational diabetes mellitus preeclampsia |
| url | https://www.mdpi.com/2072-6643/15/11/2459 |
| work_keys_str_mv | AT yushuqin understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT donalynbily understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT makaylaaguirre understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT kezhang understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia AT linglinxie understandingpparganditsagonistsontrophoblastdifferentiationandinvasionpotentialtherapeutictargetsforgestationaldiabetesmellitusandpreeclampsia |